Compass TherapeuticsCMPX
NASDAQBiotech
No cached AI snapshot yet for CMPX.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
39 employees180.09M shares outstandinglisted 2020-11-13
Next earnings ~May 5, 2026
About Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Latest News
Showing market-wide stock news
USD/JPY Price Forecast: Retreats from 155.50 with Fed’s policy in focus
Equities: Fed focus and energy shock – Deutsche Bank
Euro makes a run at 1.15, December hike groundwork is set to continue
Factbox-Major brokerages’ forecasts for S&P 500 index in 2026
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
Related Stocksin Biotech
Ready to see the live AI view on CMPX?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing CMPX side-by-side with live signals.